TCL Archive Pfizer’s Inlyta Gives FDA a Teaching Moment: Not All PFS Advantages Are Created Equal December 16, 2011
TCL Archive In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List December 2, 1983
TCL Archive ASCO Highlights Six Studies From Meeting To Showcase Advances In Cancer Care May 30, 2008